PMID- 26371891
OWN - NLM
STAT- MEDLINE
DCOM- 20160920
LR  - 20240324
IS  - 1918-1523 (Electronic)
IS  - 1203-6765 (Print)
IS  - 1203-6765 (Linking)
VI  - 20
IP  - 6
DP  - 2015 Nov-Dec
TI  - Nitrous oxide persistently alleviates pain hypersensitivity in neuropathic rats: 
      A dose-dependent effect.
PG  - 309-15
LID - 16866 [pii]
AB  - BACKGROUND: Despite numerous pharmacological approaches, there are no common 
      analgesic drugs that produce meaningful relief for the majority of patients with 
      neuropathic pain. Although nitrous oxide (N2O) is a weak analgesic that acts via 
      opioid-dependent mechanisms, it is also an antagonist of the N-methyl-D-aspartate 
      receptor (NMDAR). The NMDAR plays a critical role in the development of pain 
      sensitization induced by nerve injury. OBJECTIVE: Using the chronic constriction 
      injury of the sciatic nerve in male rats as a preclinical model of neuropathic 
      pain, the first aim of the present study was to evaluate the lowest N2O 
      concentration and the shortest time of N2O postinjury exposure that would produce 
      persistent relief of neuropathic pain. The second aim was to compare the effects 
      of N2O with gabapentin, a reference drug used in human neuropathic pain relief. 
      METHODS: Changes in the nociceptive threshold were evaluated using the paw 
      pressure vocalization test in rats. RESULTS: Among the various N2O concentrations 
      tested, which ranged from 25% to 50%, only 50% N2O single exposure for 1 h 15 min 
      induced a persistent (minimum of three weeks) and significant (60%) reduction in 
      pain hypersensitivity. A single gabapentin dose (75 mg⁄kg to 300 mg⁄kg, 
      intraperitoneally) induced an acute (1 h to 1 h 30 min) dose-dependent effect, 
      but not a persistent effect such as that observed with N2O. CONCLUSIONS: These 
      preclinical results suggest that N2O is advantageous for long-lasting neuropathic 
      pain relief after sciatic nerve injury compared with other drugs used in humans 
      such as gabapentinoids or NMDAR antagonists. The present preclinical study 
      provides a rationale for developing comparative clinical studies.
FAU - Ben Boujema, Meric
AU  - Ben Boujema M
FAU - Laboureyras, Emilie
AU  - Laboureyras E
FAU - Pype, Jan
AU  - Pype J
FAU - Bessiere, Baptiste
AU  - Bessiere B
FAU - Simonnet, Guy
AU  - Simonnet G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150915
PL  - United States
TA  - Pain Res Manag
JT  - Pain research & management
JID - 9612504
RN  - 0 (Amines)
RN  - 0 (Analgesics)
RN  - 0 (Cyclohexanecarboxylic Acids)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - 6CW7F3G59X (Gabapentin)
RN  - K50XQU1029 (Nitrous Oxide)
SB  - IM
MH  - Amines/therapeutic use
MH  - Analgesics/*therapeutic use
MH  - Animals
MH  - Cyclohexanecarboxylic Acids/therapeutic use
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Gabapentin
MH  - Hyperalgesia/*drug therapy/etiology
MH  - Male
MH  - Neuralgia/*drug therapy/*physiopathology
MH  - Nitrous Oxide/*therapeutic use
MH  - Pain Measurement
MH  - Pain Threshold/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Treatment Outcome
MH  - gamma-Aminobutyric Acid/therapeutic use
PMC - PMC4676501
EDAT- 2015/09/16 06:00
MHDA- 2016/09/22 06:00
PMCR- 2015/11/01
CRDT- 2015/09/16 06:00
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/09/22 06:00 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - 16866 [pii]
AID - prm-20-309 [pii]
AID - 10.1155/2015/809059 [doi]
PST - ppublish
SO  - Pain Res Manag. 2015 Nov-Dec;20(6):309-15. doi: 10.1155/2015/809059. Epub 2015 
      Sep 15.